Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

Please provide your email address to receive an email when new articles are posted on . Two small interfering RNA therapies lowered triglyceride levels in patients with mixed hyperlipidemia at 24 ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

(MENAFN- EIN Presswire) EINPresswire/ -- The RNA interference (RNAi) technology market has been experiencing remarkable growth recently, driven by advances in genetic research and increasing interest ...

Cardiometabolic disease isn’t a big part of Roche’s drug portfolio or pipeline, but the pharmaceutical giant is trying to change that with a deal to share in the development of an experimental Alnylam ...

Small interference RNAs (siRNAs) have shown great potential as gene silencing reagents in a wide range of experimental systems. In the 4 July Nature, Anton McCaffrey and colleagues at the Stanford ...

RNA interference (RNAi) takes place in the nuclei of human cells, according to a group from the University of Massachusetts Medical School. Tariq M. Rana, a coauthor on the study, says that until now ...